Needham & Company LLC Raises Artivion (NYSE:AORT) Price Target to $30.00

Artivion (NYSE:AORT) had its price target upped by equities research analysts at Needham & Company LLC from $25.00 to $30.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s target price would suggest a potential upside of 42.38% from the company’s previous close.

Separately, Stifel Nicolaus lifted their price objective on Artivion from $20.00 to $22.00 and gave the company a “buy” rating in a report on Friday, February 16th.

Artivion Stock Up 0.7 %

AORT opened at $21.07 on Tuesday. Artivion has a fifty-two week low of $12.16 and a fifty-two week high of $21.90. The company has a market capitalization of $868.08 million, a P/E ratio of -28.09 and a beta of 1.66. The stock has a fifty day moving average of $20.40 and a 200-day moving average of $18.06. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.43 and a current ratio of 4.85.

Artivion (NYSE:AORT) last announced its earnings results on Monday, May 6th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.04. Artivion had a negative net margin of 8.67% and a positive return on equity of 3.02%. During the same quarter last year, the firm posted $0.02 EPS. On average, equities analysts expect that Artivion will post 0.26 EPS for the current year.

Insider Buying and Selling at Artivion

In related news, SVP Marshall S. Stanton sold 2,183 shares of Artivion stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $20.39, for a total value of $44,511.37. Following the transaction, the senior vice president now directly owns 83,296 shares of the company’s stock, valued at $1,698,405.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Marshall S. Stanton sold 2,183 shares of the company’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $20.39, for a total transaction of $44,511.37. Following the completion of the sale, the senior vice president now directly owns 83,296 shares in the company, valued at approximately $1,698,405.44. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO James P. Mackin sold 13,996 shares of Artivion stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $18.72, for a total value of $262,005.12. Following the completion of the transaction, the chief executive officer now owns 705,562 shares in the company, valued at approximately $13,208,120.64. The disclosure for this sale can be found here. Insiders have sold a total of 149,952 shares of company stock valued at $2,891,627 in the last ninety days. 8.10% of the stock is currently owned by company insiders.

Institutional Trading of Artivion

Hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC acquired a new position in Artivion in the 3rd quarter worth about $188,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Artivion by 97.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,322 shares of the company’s stock worth $126,000 after buying an additional 4,099 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Artivion by 6.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,628 shares of the company’s stock worth $267,000 after acquiring an additional 1,133 shares during the last quarter. Silverleafe Capital Partners LLC acquired a new position in Artivion in the 3rd quarter valued at approximately $152,000. Finally, Mesirow Financial Investment Management Inc. bought a new position in shares of Artivion during the third quarter valued at $251,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.